Literature DB >> 15081866

Inhibition of 3T3-L1 adipocyte differentiation by 6-ethoxyzolamide: repressed peroxisome proliferator-activated receptor gamma mRNA and enhanced CCAAT/enhancer binding protein beta mRNA levels.

Takenori Takahata1, Takayuki Kumano, Keizou Ookawa, Makoto Hayakari, Ikuko Kakizaki, Shigeki Tsuchida.   

Abstract

The effects of 6-ethoxyzolamide (ETZ), a carbonic anhydrase (CA) inhibitor, on differentiation of the mouse preadipocyte cell line 3T3-L1 were examined by quantitative image analysis of intracellular fat storage. For adipocyte differentiation, postconfluent cells were treated with a ligand of the peroxisome proliferator-activated receptor gamma (PPARgamma), troglitazone (TRG), and dexamethasone for 2 days. Differentiated cells showed weak fat staining at day 4 which increased thereafter, correlating with CAIII expression. ETZ treatment for 10 days at a 200microM concentration reduced both the percentage of differentiated adipocytes storing fat and the amount of fat stored in individual cells. These findings were also supported by the results of fluorescence activated cell sorting analysis. Despite their light fat staining, however, CAIII was not expressed in ETZ-treated cells. Furthermore, ETZ delayed the clonal expansion of cells, an early event preceding differentiation. Northern blot analysis revealed a high CCAAT/enhancer binding protein (C/EBP) beta mRNA level and low PPARgamma mRNA in ETZ-treated cells. Thus, increased C/EBPbeta mRNA did not lead to enhanced PPARgamma expression in this case. Another CA inhibitor acetazolamide did not inhibit adipocyte differentiation, although the drug exhibited a similar inhibition pattern for CA activity as ETZ. These results suggested that inhibitory effects of ETZ on adipocyte differentiation were not due to inhibition of CA activity but rather due to altered levels of the transcription factors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15081866     DOI: 10.1016/j.bcp.2003.12.039

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

1.  Carbonic anhydrase inhibition prevents and reverts cardiomyocyte hypertrophy.

Authors:  Bernardo V Alvarez; Danielle E Johnson; Daniel Sowah; Daniel Soliman; Peter E Light; Ying Xia; Morris Karmazyn; Joseph R Casey
Journal:  J Physiol       Date:  2006-11-23       Impact factor: 5.182

2.  Myostain is involved in ginsenoside Rb1-mediated anti-obesity.

Authors:  Hong-Shi Li; Jiang-Ying Kuang; Gui-Jun Liu; Wei-Jie Wu; Xian-Lun Yin; Hao-Dong Li; Lei Wang; Tao Qin; Wen-Cheng Zhang; Yuan-Yuan Sun
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

3.  Fatty acid synthase-positive hepatocytes and subsequent steatosis in rat livers by irinotecan.

Authors:  Takeyuki Sawano; Takeshi Shimizu; Toshiyuki Yamada; Naoki Nanashima; Takuya Miura; Satoko Morohashi; Daisuke Kudo; Feng Mao Hui; Hiroshi Kijima; Kenichi Hakamada; Shigeki Tsuchida
Journal:  Oncol Rep       Date:  2015-02-20       Impact factor: 3.906

4.  Inhibitory Effect of Bacterial Lysates Extracted from Pediococcus acidilactici on the Differentiation of 3T3-L1 Pre-Adipocytes.

Authors:  Han Bin Lee; Seok-Seong Kang
Journal:  Int J Mol Sci       Date:  2022-10-01       Impact factor: 6.208

5.  Caveolae-Associated Protein 3 (Cavin-3) Influences Adipogenesis via TACE-Mediated Pref-1 Shedding.

Authors:  Phil June Park; Sung Tae Kim
Journal:  Int J Mol Sci       Date:  2020-07-15       Impact factor: 5.923

6.  Carbonic anhydrase 3 increases during liver adipogenesis even in pre-obesity, and its inhibitors reduce liver adipose accumulation.

Authors:  Hiroyuki Yamamoto; Naoto Uramaru; Azusa Kawashima; Toshiyuki Higuchi
Journal:  FEBS Open Bio       Date:  2022-02-10       Impact factor: 2.693

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.